Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Feb 18;14:10. doi: 10.1186/s12944-015-0004-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Li et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Plasma lipids levels in both groups during follow-up. ACS patients with T2DM divided into two groups, the combination group who received EZ 10 mg/d with standard dose of statins (n=44) and statins group who received standard dose of statins (n=40). Plasma lipids levels were tested at baseline, 7^th day and 30^th day after treatment. (A) LDL-C levels and control rate of LDL-C. *Indicate the percentage control rate of LDL-C level, P=0.002. (B, C, D) TC, TG, HDL-C levels. *p=0.000 versus TG level at baseline in combination group.#p=0.000 versus TG level at baseline in statins group. Data are shown as mean ± SE. Independent t test was to compare the significant difference of treatment groups. Data expressed as as mean ± SE.